{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+hydrochloride&page=2", "query": { "intervention": "Bendamustine hydrochloride", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+hydrochloride&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T09:55:49.731Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03570892", "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy", "type": "DRUG" }, { "name": "Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 330, "start_date": "2019-05-09", "completion_date": "2026-02-03", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03570892" }, { "nct_id": "NCT06241456", "title": "FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "FT825", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2024-01-05", "completion_date": "2044-05-01", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 14, "location_summary": "Gilbert, Arizona • La Jolla, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06241456" }, { "nct_id": "NCT02059239", "title": "Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Autologous Stem Cell Transplantation", "type": "BIOLOGICAL" }, { "name": "Allogeneic Stem Cell Transplantation", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2014-06-04", "completion_date": "2020-06-15", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02059239" }, { "nct_id": "NCT03269669", "title": "Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2018-01-23", "completion_date": "2027-01-21", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 429, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03269669" }, { "nct_id": "NCT01222260", "title": "Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-01", "completion_date": "2019-07-03", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222260" }, { "nct_id": "NCT03997968", "title": "A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignancy", "Non-hodgkin Lymphoma", "Multiple Myeloma", "Breast Cancer", "Ovarian Cancer", "Soft Tissue Sarcoma", "Head and Neck Cancer", "DLBCL", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Pancreatic Cancer", "CLL", "Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "CYT-0851", "type": "DRUG" }, { "name": "CYT-0851 in combination with gemcitabine", "type": "DRUG" }, { "name": "CYT-0851 in combination with capecitabine", "type": "DRUG" }, { "name": "CYT-0851 in combination with rituximab and bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cyteir Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-10-09", "completion_date": "2024-12-20", "has_results": false, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 16, "location_summary": "San Francisco, California • Stanford, California • Denver, Colorado + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03997968" }, { "nct_id": "NCT01352312", "title": "Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "B-Cell Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-05-25", "completion_date": "2018-05-10", "has_results": false, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01352312" }, { "nct_id": "NCT03739619", "title": "Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Classical Hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-11-26", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739619" }, { "nct_id": "NCT02728531", "title": "Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Autologous stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 18, "start_date": "2016-04-18", "completion_date": "2023-08-16", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728531" }, { "nct_id": "NCT05023980", "title": "A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 282, "start_date": "2021-09-23", "completion_date": "2027-10", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-29T09:55:49.731Z", "location_count": 5, "location_summary": "Los Angeles, California • Whittier, California • Coral Springs, Florida + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Brick", "state": "New Jersey" }, { "city": "Westbury", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05023980" } ] }